Loading…
Disclosed for 95 months, Jul 2017 to Sep 2026.
UTI - Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In May 2018 it disclosed 27 stocks worth ₹385 Cr, down ₹26 Cr from Apr 2018. Its largest positions were Sun Pharmaceutical Industries Limited (9.1%), Cipla Limited (8.6%), Alkem Laboratories Limited (8.3%); the ten largest together made up 65.2% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 82.7% of its equity. Cash and debt stood at 3.7%. Compared with Apr 2018 the fund entered 1 new stock and exited 1.
Top-10 weight is higher than 90% of peers
Holds more stocks than 11% of peers
Holds more cash than 54% of peers
What these mean: concentration · cash
Every line the fund disclosed, with the change against Apr 2018. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 9.10% | up 3.33 pts | ₹35 Cr | up ₹11.3 Cr | Added |
| Cipla Limited | 8.58% | up 0.76 pts | ₹33 Cr | up ₹88 L | Added |
| Alkem Laboratories Limited | 8.28% | down 0.28 pts | ₹31.9 Cr | down ₹3.3 Cr | Trimmed |
| Torrent Pharmaceuticals Limited | 7.82% | down 0.23 pts | ₹30.1 Cr | down ₹3 Cr | Trimmed |
| Pfizer Limited | 7.52% | up 0.80 pts | ₹28.9 Cr | up ₹1.3 Cr | Added |
| IPCA Laboratories Limited | 6.04% | down 0.30 pts | ₹23.2 Cr | down ₹2.8 Cr | Trimmed |
| Sanofi India Limited | 5.26% | up 0.47 pts | ₹20.2 Cr | up ₹56 L | Added |
| Aurobindo Pharma Limited | 4.52% | down 1.31 pts | ₹17.4 Cr | down ₹6.5 Cr | Trimmed |
| Divi's Laboratories Limited | 4.14% | down 0.66 pts | ₹15.9 Cr | down ₹3.8 Cr | Trimmed |
| Ajanta Pharma Limited | 3.97% | down 1.27 pts | ₹15.3 Cr | down ₹6.2 Cr | Trimmed |
| Dishman Carbogen Amcis Limited | 3.78% | down 0.51 pts | ₹14.5 Cr | down ₹3.1 Cr | Trimmed |
| Cash, TREPS & receivables | 3.73% | up 1.37 pts | ₹14.3 Cr | up ₹4.7 Cr | Added |
| FDC Limited | 2.97% | up 0.07 pts | ₹11.4 Cr | down ₹50 L | Trimmed |
| Max India Limited | 2.72% | up 0.43 pts | ₹10.5 Cr | up ₹1.1 Cr | Added |
| Zydus Lifesciences Limited | 2.68% | down 0.19 pts | ₹10.3 Cr | down ₹1.5 Cr | Trimmed |
| Natco Pharma Limited | 2.63% | up 0.17 pts | ₹10.1 Cr | down ₹0 L | Held |
| Thyrocare Technologies Limited | 2.33% | down 0.06 pts | ₹8.9 Cr | down ₹85 L | Trimmed |
| Lupin Limited | 2.20% | up 2.20 pts | ₹8.5 Cr | up ₹8.5 Cr | New |
| Dr. Reddy's Laboratories Limited | 2.11% | up 0.98 pts | ₹8.1 Cr | up ₹3.5 Cr | Added |
| Narayana Hrudayalaya Limited | 2.02% | down 0.22 pts | ₹7.8 Cr | down ₹1.4 Cr | Trimmed |
| Dr. Lal Path Labs Limited | 1.77% | up 0.14 pts | ₹6.8 Cr | up ₹13 L | Added |
| Strides Pharma Science Limited | 1.72% | down 2.39 pts | ₹6.6 Cr | down ₹10.3 Cr | Trimmed |
| Indoco Remedies Limited | 1.67% | up 0.09 pts | ₹6.4 Cr | down ₹7 L | Trimmed |
| Sun Pharma Advanced Research Company Limited | 1.39% | up 0.04 pts | ₹5.4 Cr | down ₹20 L | Trimmed |
| Apollo Hospitals Enterprise Limited | 0.48% | down 0.04 pts | ₹1.8 Cr | down ₹27 L | Trimmed |
| Shilpa Medicare Limited | 0.29% | down 0.03 pts | ₹1.1 Cr | down ₹20 L | Trimmed |
| EQ SOLARA ACTIVE PHARMA SCIENCES LTD | 0.14% | up 0.01 pts | ₹56 L | — | Held |
| Unichem Laboratories Limited | 0.14% | down <0.01 pts | ₹55 L | down ₹6 L | Trimmed |
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Compared with
Since Apr 2018, the weight rose most in Pharmaceuticals & Biotechnology (+5.8 pts) and Healthcare Services (+0.4 pts), and fell most in Finance (−3.5 pts) and Pharmaceuticals (−2.8 pts).
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
| Sector | Oct 2017 | Feb 2018 | Apr 2018 | May 2018 |
|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 71.7% | 76.0% | 76.9% | 82.7% |
| Healthcare Services | 9.5% | 9.7% | 9.3% | 9.7% |
| Pharmaceuticals | 14.8% | 11.0% | 10.4% | 7.6% |
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.
| Jun 2026 | ₹1,308 Cr | 42 | 0 | 0 | 5.0% | 5.0% | — |
| May 2026 | ₹1,217 Cr | 42 | 0 | 1 | 5.5% | 5.5% | — |
| Apr 2026 | ₹1,144 Cr | 43 | 0 | 0 | 4.8% | 4.7% | — |
| Mar 2026 | ₹1,056 Cr | 43 | 0 | 0 | 1.3% | 1.3% | — |
| Feb 2026 | ₹1,107 Cr | 43 | 0 | 0 | 1.8% | 1.8% | — |
| Jan 2026 | ₹1,055 Cr | 43 | 1 | 1 | 1.2% | 1.2% | — |
| Dec 2025 | ₹1,102 Cr | 43 | 0 | 0 | 0.6% | 0.6% | — |
| Nov 2025 | ₹1,126 Cr | 43 | 1 | 0 | 1.3% | 1.3% | — |
| Oct 2025 | ₹1,125 Cr | 42 | 2 | 0 | 1.9% | 1.9% | — |
| Jun 2025 | ₹1,099 Cr | 40 | 1 | 3 | 1.1% | 1.1% | — |
| Apr 2025 | ₹1,037 Cr | 42 | 0 | 1 | 1.1% | 1.1% | — |
| Mar 2025 | ₹1,042 Cr | 43 | 0 | 0 | 0.8% | 0.8% | — |
| Feb 2025 | ₹1,057 Cr | 43 | 1 | 0 | 0.5% | 0.4% | — |
| Jan 2025 | ₹1,150 Cr | 42 | 1 | 1 | 2.1% | 2.3% | — |
| Dec 2024 | ₹1,236 Cr | 42 | 1 | 0 | 2.3% | 2.4% | — |
| Nov 2024 | ₹1,203 Cr | 41 | 0 | 0 | 2.0% | 2.1% | — |
| Oct 2024 | ₹1,187 Cr | 41 | 2 | 0 | 1.4% | 1.5% | — |
| Sep 2024 | ₹1,201 Cr | 39 | 1 | 0 | 3.3% | 3.4% | — |
| Aug 2024 | ₹1,168 Cr | 38 | 0 | 1 | 2.4% | 2.5% | — |
| Jul 2024 | ₹1,089 Cr | 39 | 2 | 1 | 1.0% | 1.1% | — |
| Apr 2024 | ₹943 Cr | 38 | 0 | 0 | 1.4% | 1.5% | — |
For any of the 71 earlier months, choose it in “Portfolio as of” at the top of the page.